

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claims 1-10 canceled.

11. (new) A peptide selected from
 - (a) a peptide comprising the amino acid sequence represented by SEQ ID NO:1;
 - (b) a peptide comprising the amino acid sequence represented by SEQ ID NO:2;
 - (c) a peptide comprising the amino acid sequence represented by SEQ ID NO:3;
 - (d) a peptide comprising an amino acid sequence in which one or more amino acids are added to the amino acid sequence represented by SEQ ID NO:1, and having activity of inhibiting angiotensin-converting enzyme;
 - (e) a peptide comprising an amino acid sequence in which one or more amino acids are added to the amino acid sequence represented by SEQ ID NO:2, and having activity of inhibiting angiotensin-converting enzyme; and
 - (f) a peptide comprising an amino acid sequence in which one or more amino acids are added to the amino acid sequence represented by SEQ ID NO:3, and having activity of inhibiting angiotensin-converting enzyme.
12. (new) An inhibitor for an angiotensin-converting enzyme, which comprises the peptide according to claim 11 as an active ingredient.
13. (new) A food or drink comprising the peptide according to claim 11.

Preliminary Amendment
National Stage Entry for PCT/JP04/018235

14. (new) A pharmaceutical composition comprising the peptide according to claim 11 as an active ingredient.

15. (New) The food or drink according to claim 13, which is an agent for preventing and/or treating diseases caused by abnormality of an angiotensin-converting enzyme.

16. (New) The pharmaceutical composition according to claim 14, which is an agent for preventing and/or treating diseases caused by abnormality of an angiotensin-converting enzyme.

17. (New) A method of inhibiting an angiotensin-converting enzyme, which comprises administering to a subject in need thereof an effective amount of the peptide according to claim 11.

18. (New) A method of preventing and/or treating diseases caused by abnormality of an angiotensin-converting enzyme, which comprises administering to a subject in need thereof an effective amount of the peptide according to claim 11.